Sofosbuvir (Sovaldi)
Sofosbuvir is a nucleotide polymerase inhibitor that blocks the HCV NS5B enzyme the virus needs to copy itself. It is not used alone — it forms the backbone of combination DAA regimens, including Harvoni.
Explore this therapy:
AI Summary Most patients who complete an 8- to 12-week course of DAA therapy such as Harvoni or Mavyret reach sustained virologic response (SVR), or cure.
HCV Direct-Acting Antivirals (DAAs)
Medically reviewed.
HCV direct-acting antivirals (DAAs) are oral medications used to treat chronic hepatitis C virus (HCV) infection by targeting the proteins the virus needs to replicate. Care for hepatitis C typically combines these antiviral medications with lifestyle changes, weight management support, and ongoing monitoring to protect the liver during and after treatment. Because response to therapy and disease severity vary from person to person, treatment plans are personalized based on overall health, liver disease stage, and individual needs.
You can explore the different HCV DAA treatment options below and learn how each therapy may support your path to a cure and long-term liver health. Connecting with a liver specialist can help you understand which option fits your diagnosis and receive personalized guidance and ongoing care throughout treatment.
On this page
Liver Health AI Assistant
Ask Aimy
Turn confusion into a better next question.
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
HCV DAA THERAPY OVERVIEW
What is HCV DAA Therapy and Who May Benefit
Direct-acting antivirals (DAAs) are oral medications that target specific proteins the hepatitis C virus (HCV) needs to replicate. Unlike older interferon-based treatments, DAA regimens are interferon-free, usually well tolerated, and taken for a defined course of weeks rather than indefinitely. Care built around these medications combines the drug with regular monitoring, and treatment choice is personalized based on HCV genotype, liver disease stage, prior treatment history, and overall health.
You can explore the individual HCV DAA therapies below and learn how they help most patients reach a cure, known as sustained virologic response (SVR). Because eligibility depends on your specific diagnosis and health history, connecting with a liver specialist can help you understand which option fits your care plan.
Harvoni (Ledipasvir/Sofosbuvir)
Harvoni combines two antivirals in a single once-daily tablet. Ledipasvir blocks the HCV NS5A protein and sofosbuvir blocks the NS5B polymerase, together stopping viral replication at multiple stages. It is typically used for HCV genotype 1, 4, 5, or 6.
Explore this therapy:
Mavyret (Glecaprevir/Pibrentasvir)
Mavyret pairs a protease inhibitor with an NS5A inhibitor to work against all major HCV genotypes (1 through 6). Most people complete treatment in as little as 8 weeks.
Explore this therapy:
Who may benefit
Healthcare providers typically prescribe DAA therapy for people with confirmed chronic HCV infection who need combination antiviral treatment. The specific regimen depends on HCV genotype, whether cirrhosis is present, and any prior treatment history.
DIET & LIFESTYLE SUPPORT
How Lifestyle Changes Support HCV DAA Therapy
HCV DAA therapy works best when combined with liver-protective habits. Nutrition, avoiding alcohol, and preventing reinfection all support the cure these medications help you achieve.
Liver-friendly diet
A balanced, liver-friendly diet and staying well hydrated support your liver while it clears the hepatitis C virus during treatment.
Avoiding alcohol and reinfection risk
Avoiding alcohol during and after treatment protects the liver, and avoiding behaviors that risk reinfection helps preserve your cure once you reach sustained virologic response (SVR).
Managing related liver conditions
Managing other conditions that affect liver health, such as fatty liver disease, supports overall liver recovery alongside antiviral treatment.
Support your diet alongside treatment
A nutrition bar designed for liver health can be a simple way to support your eating habits during treatment.
Explore Liver Health Nutrition Bars
Connect with a liver specialist to discuss whether HCV DAA therapy fits your care plan.
WHY CURING HEPATITIS C MATTERS
How HCV DAA Therapy Protects Long-Term Liver Health
Curing hepatitis C with DAA therapy does more than clear the virus from the blood. Eradicating HCV helps prevent the disease from progressing to cirrhosis and reduces the risk of hepatocellular carcinoma (liver cancer), especially in patients who already have liver fibrosis.
Because DAAs are pan-genotypic in some regimens and generally well tolerated, they have replaced older interferon-based therapies as the standard approach to hepatitis C treatment.
Reducing cancer and cirrhosis risk
For patients with HCV infection and liver fibrosis, direct-acting antivirals are recommended to reduce cirrhosis-related complications, including the risk of hepatocellular carcinoma (HCC).
Pan-genotypic treatment options
DAA regimens such as Mavyret work against all major HCV genotypes (1 through 6), simplifying treatment decisions compared with older, genotype-specific therapies.
Treatment options for kidney disease
Even people with reduced kidney function can be treated. Some DAA regimens, including glecaprevir/pibrentasvir, are suitable options for patients with severe renal impairment.
Sustained virologic response (SVR)
Most people completing a course of DAA therapy reach sustained virologic response (SVR), considered a cure. Avoiding reinfection risk behaviors after cure helps protect this result.
TREATMENT MONITORING
Monitoring Liver Health During HCV DAA Therapy
Regular monitoring helps your healthcare provider track how your body responds to HCV DAA therapy and confirm the virus has cleared. Follow-up care may include blood tests and viral load checks during and after treatment.
HCV RNA (viral load) testing
Providers repeat HCV RNA testing during and after treatment to confirm the virus is being cleared and to document sustained virologic response (SVR).
Blood tests
Liver function tests track enzymes and other markers that show how your liver is responding to treatment and help flag any changes early.
Ongoing liver monitoring
For patients with cirrhosis or advanced fibrosis, providers may continue liver imaging and cancer screening even after a successful cure, since curing HCV lowers but does not fully eliminate future risk.
Only a qualified healthcare provider can adjust your treatment plan based on your test results and health history.
COMMON QUESTIONS
Answers to Common HCV DAA Therapy Questions
What are HCV direct-acting antivirals used for?
HCV direct-acting antivirals (DAAs) are oral medications used to treat chronic hepatitis C virus (HCV) infection. Options include sofosbuvir (Sovaldi), ledipasvir/sofosbuvir (Harvoni), and glecaprevir/pibrentasvir (Mavyret). These medicines target specific viral proteins to stop HCV from replicating, and most people who complete a course reach a cure, known as sustained virologic response (SVR). Talk with your liver specialist to see if this therapy fits your treatment plan.
How do direct-acting antivirals work in the body?
DAAs work by blocking proteins the hepatitis C virus needs to copy itself. Sofosbuvir blocks the NS5B polymerase enzyme, while ledipasvir and pibrentasvir block the NS5A protein, and glecaprevir blocks the NS3/4A protease. Because these drugs target the virus at multiple stages, combination regimens rapidly reduce HCV levels in the blood and help most patients reach sustained virologic response (SVR). Your healthcare provider can explain how a specific regimen applies to your HCV genotype and health history.
Who qualifies for HCV DAA therapy?
Healthcare providers generally consider DAA therapy for adults with chronic HCV infection who need combination antiviral treatment. The choice of regimen depends on HCV genotype, whether cirrhosis is present, kidney function, and prior treatment history. Pan-genotypic options like Mavyret work across all major genotypes, while Harvoni is typically used for genotypes 1, 4, 5, or 6. Only a qualified healthcare provider can determine which DAA regimen is right for your specific situation.
How effective is DAA therapy for hepatitis C, and how long does treatment take?
Most people treated with modern DAA regimens reach sustained virologic response (SVR), considered a cure for hepatitis C. Treatment courses are typically 8 to 12 weeks, though duration can extend to 24 weeks for some patients depending on genotype, prior treatment history, and presence of cirrhosis. Curing HCV helps reduce the risk of cirrhosis-related complications, including liver cancer, in patients with fibrosis. Discuss your expected treatment length and outlook with your healthcare provider.
What are the common side effects of HCV DAA therapy?
The most commonly reported side effects across DAA regimens are fatigue, headache, and nausea. Some regimens are also associated with diarrhea or insomnia, and sofosbuvir-based treatment used with ribavirin can cause anemia. Most side effects are mild to moderate. Your healthcare provider will monitor you regularly during treatment and can help manage any side effects that arise.
Does curing hepatitis C mean I no longer need liver monitoring?
No, curing hepatitis C does not remove all future risk, especially for people who already have cirrhosis or advanced fibrosis. DAA therapy works alongside continued liver monitoring, avoiding alcohol, and preventing reinfection risk behaviors. Providers may continue liver imaging and cancer screening even after a successful cure. Ask your healthcare provider what ongoing monitoring makes sense for your situation.
Are all HCV DAA regimens the same?
Yes, DAA regimens differ by genotype coverage, pill burden, and treatment duration. Sofosbuvir is used only in combination with other DAAs, Harvoni combines two antivirals for genotypes 1, 4, 5, or 6, and Mavyret is a pan-genotypic option usually completed in 8 weeks. Some regimens, such as glecaprevir/pibrentasvir, are also suitable for patients with severe kidney impairment. Your healthcare provider will choose the regimen best suited to your genotype and overall health.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.